Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study

BACKGROUND: Lymphocyte-activation gene 3 (LAG-3), a checkpoint molecule contributing to immune suppressive microenvironment, is regarded as a promising target in cancer treatment. SHR-1802 is a novel anti-LAG-3 monoclonal antibody. OBJECTIVES: To evaluate the safety, tolerability, pharmacokinetics,...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Ting, Liu, Zhigang, Han, Zhengquan, Zhou, Huan, Liu, Rui, Li, Yijing, Li, Shaorong, Xiu, Peng, Wang, Shuni, Zhang, Yiping, Ba, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387801/
https://www.ncbi.nlm.nih.gov/pubmed/37529157
http://dx.doi.org/10.1177/17588359231186025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387801/
https://www.ncbi.nlm.nih.gov/pubmed/37529157
http://dx.doi.org/10.1177/17588359231186025

Ejemplares similares